Warp Sciences, an AI-powered chemical R&D service provider, co-founded by Kevin Weil, the former Vice President of Science at OpenAI, has officially entered the market. The company announced that it has successfully secured $215 million in funding, bringing its post-money valuation to an impressive $865 million. Warp Sciences specializes in analog synthesis during the lead compound optimization stage of drug development. It intends to replace conventional manual synthesis methods with robots and train AI models and robots through a closed-loop system of real-world experimental data. The goal is to expedite and cut costs in the synthesis process while fostering scientific superintelligence. Warp Sciences operates on a fee-for-delivery-of-compounds model and primarily caters to the domestic U.S. market. It aims to offer cost-effectiveness on par with overseas Contract Research Organizations (CROs) while maintaining compliance. Presently, the company works with a select few design partners and does not engage in independent drug development; rather, it concentrates on constructing R&D infrastructure for pharmaceutical companies. Although the sector already features competitors such as traditional CROs, top model vendors, and up-and-coming automated laboratory firms, and the trend of reshoring in the pharmaceutical industry, spurred by U.S. biosecurity policies, presents short-term demand opportunities for the company, Warp Sciences has not yet released key performance metrics like turnaround time and costs. Its future performance is yet to be determined.